Display options
Cite
Arjomand Fard N, Tabrizian N, Mirzaei R, et al. Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells. Iran J Public Health. 2017;46(2):216-221
Arjomand Fard, N., Tabrizian, N., Mirzaei, R., Hadjati, J., Tofighi Zavareh, F., Salehi Nodeh, A. R., & Mirshafiey, A. (2017). Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells. Iranian journal of public health, 46(2), 216-221.
Arjomand Fard, Nazanin, et al. "Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells." Iranian journal of public health vol. 46,2 (2017): 216-221.
Arjomand Fard N, Tabrizian N, Mirzaei R, Hadjati J, Tofighi Zavareh F, Salehi Nodeh AR, Mirshafiey A. Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells. Iran J Public Health. 2017 Feb;46(2):216-221. PMID: 28451557; PMCID: PMC5402780.
Copy Download .nbib Format: NLM
Share it on

Iran J Public Health. 2017 Feb;46(2):216-221.

Efficacy and Safety of G2013 as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells.

Iranian journal of public health

Nazanin Arjomand Fard, Nakisa Tabrizian, Reza Mirzaei, Jamshid Hadjati, Farzaneh Tofighi Zavareh, Ali Reza Salehi Nodeh, Abbas Mirshafiey

Affiliations

  1. Dept. of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Tehran, Iran.
  2. Dept. of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  3. Dept. of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 28451557 PMCID: PMC5402780

Abstract

BACKGROUND: The expanse of dendritic cells (DC) differentiation plays an important role in determining immune response. DC-based immunosuppressive drugs have notable side effects in increasing the risk of infectious diseases and cancers. G2013, as a novel anti-inflammatory and immunosuppressive agent, has been tested in experimental model of multiple sclerosis. The aim of this study was to conduct the safety property of G2013 on dendritic cells biology.

METHODS: The effect of G2013 on differentiation, maturation, and function of dendritic cells was examined at Tehran University in 2014. To investigate how G2013 affects human dendritic cells (DC) in a defined inflammatory environment, human peripheral blood mononuclear cells (PBMC) were isolated from healthy blood. Monocytes were then purified using anti-CD14 microbeads. Monocytes were treated with G2013 in two different doses (6 and 12 μg/well) along with adding granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 for inducing monocytes to immature DC and adding lipopolysaccharide for running DC maturation. Differentiation, maturation, and function of dendritic cells were examined with flow cytometry and ELISA.

RESULTS: G2013 therapy had no significant effect on CD83, CD86 and DR expression, as well as IL-10 and IL-12 cytokine levels and it, has no remarkable side on differentiation, maturation and function of dendritic cells in immature DC and mature DC process in vitro.

CONCLUSION: G2013 is a safe agent with no adverse effect on differentiation, maturation, and function of dendritic cells. It may be recommended as a novel immunosuppressive agent with no or little side effect in increasing the risk of infectious diseases and cancers.

Keywords: Anti-inflammatory agents; Dendritic cell; Immunosuppressive; NSAIDs

References

  1. Nat Rev Cancer. 2002 Jan;2(1):59-65 - PubMed
  2. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92 - PubMed
  3. Science. 2010 Feb 5;327(5966):656-61 - PubMed
  4. J Neuroimmunol. 2010 Jan 25;218(1-2):28-35 - PubMed
  5. Curr Opin Immunol. 2003 Aug;15(4):421-9 - PubMed
  6. Int J Cancer. 2008 Mar 1;122(5):1068-76 - PubMed
  7. Nature. 1998 Mar 5;392(6671):86-9 - PubMed
  8. Eur J Immunol. 1997 May;27(5):1229-35 - PubMed
  9. Acta Neurol Belg. 2015 Sep;115(3):259-66 - PubMed
  10. Annu Rev Immunol. 2003;21:685-711 - PubMed
  11. Methods Mol Biol. 2009;499:1-8 - PubMed
  12. Immunology. 2003 Oct;110(2):197-205 - PubMed
  13. Science. 1999 Feb 19;283(5405):1183-6 - PubMed
  14. ANZ J Surg. 2002 Jul;72(7):501-6 - PubMed
  15. Nature. 1998 Mar 19;392(6673):245-52 - PubMed
  16. Immune Netw. 2011 Aug;11(4):210-5 - PubMed
  17. Arthritis Rheum. 1999 Jul;42(7):1412-20 - PubMed
  18. Annu Rev Immunol. 2000;18:767-811 - PubMed
  19. Nat Rev Immunol. 2003 Dec;3(12):984-93 - PubMed
  20. Rheumatology (Oxford). 2008 Mar;47(3):355-61 - PubMed

Publication Types